Skip to main content
. 2024 Aug;86(3):452–463. doi: 10.18999/nagjms.86.3.452

Fig. 1.

Fig. 1

Flow diagram for registration of patients

Niv: nivolumab

Pem: pembrolizumab

PD-L1: programmed cell death-1 ligand 1